Sources

9 Total Sources

Boehringer Says Survodutide Cuts Liver Fat 63.1% as 16.6% Weight Loss Faces GLP-1 Rivals

Left33%

Center33%

Right33%

Boehringer Ingelheim's Survodutide Cuts Visceral, Liver Fat, Preserves Lean Mass in Obesity Study

Bloomberg21h ago

Boehringer Pitches Muscle-Sparing Obesity Drug in Crowded Field - Bloomberg

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat | The Mighty 790 KFGO | KFGO

Popular weight loss drug may slow down biological aging: Study - AOL

pharma.economictimes.indiatimes.com4h ago

Boehringer-Zealand's Survodutide: A Breakthrough in Obesity and Liver Fat Reduction, ETPharma

clinicaltrialvanguard.com8h ago

Survodutide Phase III trial shows 34% visceral fat, 63% liver fat reduction

Seeking Alpha21h ago

Boehringer's obesity drug cuts harmful belly and liver fat in late-stage trials | Seeking Alpha

MD Magazine21h ago

Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D | HCPLive

Fierce Biotech21h ago

ADA: Tolerability questions linger for Boehringer's obesity drug